These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

62 related articles for article (PubMed ID: 2480824)

  • 1. [Effects of substance P on experimental parkinsonian syndrome].
    Kryzhanovskiĭ GN; Atadzhanov MA; Kucherianu VG
    Biull Eksp Biol Med; 1989 Oct; 108(10):404-7. PubMed ID: 2480824
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Effects of difenin on experimental parkinsonian syndrome].
    Kryzhanovskiĭ GN; Atadzhanov MA; Kucherianu VG
    Biull Eksp Biol Med; 1990 Sep; 110(9):242-4. PubMed ID: 2268704
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Effects of intranasally administered substance P in parkinsonian syndrome].
    Kryzhanovskiĭ GN; Kucherianu VG; Godlevskiĭ LS; Mazarati AD
    Biull Eksp Biol Med; 1992 Jan; 113(1):16-9. PubMed ID: 1382692
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Parkinson syndrome after administration of acetylcholine into the caudate nuclei].
    Kryzhanovskiĭ GN; Atadzhanov MA; Voronina TA; Nerobkova LN
    Biull Eksp Biol Med; 1989 May; 107(5):522-5. PubMed ID: 2736276
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinico-electroencephalographic indices of the parkinsonian syndrome induced by MPP+ in rats].
    Kryzhanovski? GN; Atadzhanov MA; Voronina TA; Nerobkova LN; Zagorevski VA
    Biull Eksp Biol Med; 1989 Feb; 107(2):147-50. PubMed ID: 2784332
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Role of the striatal serotoninergic apparatus in Parkinsonian syndrome].
    Kryzanovskiĭ GN; Magaeva SV; Trekova NA; Vetrilé LA; Basharova LA; Atadzhanov MA
    Biull Eksp Biol Med; 1993 May; 115(5):466-9. PubMed ID: 8043821
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Appearance of parkinsonian syndrome after administration of delta sleep-inducing peptide into the rat substantia nigra].
    Kryzhanovskiĭ GN; Shandra AA; Godlevskiĭ LS; Mikhaleva II
    Biull Eksp Biol Med; 1990 Feb; 109(2):119-21. PubMed ID: 2337637
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The characteristics of a parkinsonian syndrome induced in an experiment by a deficiency of nigrostriatal dopamine and by stimulation of the cholinergic neurons of the caudate nucleus].
    Kryzhanovskiĭ GN; Atadzhanov MA; Voronina TA; Nerobkova LN
    Zh Nevrol Psikhiatr Im S S Korsakova; 1993; 93(6):3-7. PubMed ID: 8160497
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Formation of a generator of pathologically enhanced excitation in the caudate nucleus in experimental parkinsonism].
    Aliev MN; Igon'kina SI; Kryzhanovskiĭ GN
    Biull Eksp Biol Med; 1981 Dec; 92(12):657-9. PubMed ID: 7326408
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The effect of haloperidol at a low dose on the development of experimental parkinsonian syndrome].
    Korshunov AM; Voronina TA; Churiukanov VV; Iakhno NN
    Eksp Klin Farmakol; 1995; 58(6):7-9. PubMed ID: 8704620
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Lipid peroxidation in the caudate nuclei in experimental parkinsonian syndrome].
    Kucherianu VG; Atadzhanov MA; Nikushkin EV; Zagorevskiĭ VA; Sharkova LM
    Biull Eksp Biol Med; 1989 Jan; 107(1):39-41. PubMed ID: 2783652
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [EEG changes and symptomatic parkinsonism after intracaudate administration of dopamine antibodies].
    Kryzhanovskiĭ GN; Atadzhanov MA; Magaeva SV; Basharova LA; Vetrilé LA
    Biull Eksp Biol Med; 1989 Jan; 107(1):13-6. PubMed ID: 2914165
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Modelling of the parkinsonian syndrome by the administration of kainic acid into the caudate nucleus].
    Kryzhanovskiĭ GN; Makul'kin RF; Shandra AA; Godlevskiĭ LS; Rozhkov VS
    Biull Eksp Biol Med; 1987 Jun; 103(6):650-3. PubMed ID: 3593943
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Experimental parkinsonian syndrome in rats induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine].
    Kryzhanovskiĭ GN; Atadzhanov MA; Zagorevskiĭ VA; Sharkova LM; Voronina TA
    Biull Eksp Biol Med; 1988 Apr; 105(4):397-401. PubMed ID: 3258764
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The actions of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in animals as a model of Parkinson's disease.
    Jenner P; Marsden CD
    J Neural Transm Suppl; 1986; 20():11-39. PubMed ID: 3091760
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The effect of galanin on the experimental parkinsonian syndrome in rats induced by the intrastriatal administration of kainic acid].
    Shandra AA; Mazarati AM; Servetskiĭ KL; Kresiun VI
    Biull Eksp Biol Med; 1993 Aug; 116(8):123-5. PubMed ID: 7506070
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Analysis of sleep-wakefulness structure in parkinsonian syndrome in rats induced by 1-methyl-4-phenyl-1,2,2,6-tetrahydropyridine and oxotremorine].
    Gugutsidze DA; Nerobkova LN; Boronina TA
    Biull Eksp Biol Med; 1989 Aug; 108(8):206-9. PubMed ID: 2804326
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alterations in dopamine uptake sites and D1 and D2 receptors in cats symptomatic for and recovered from experimental parkinsonism.
    Frohna PA; Rothblat DS; Joyce JN; Schneider JS
    Synapse; 1995 Jan; 19(1):46-55. PubMed ID: 7709343
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of chronic levodopa treatment on pre- and postsynaptic markers of dopaminergic function in striatum of parkinsonian monkeys.
    Rioux L; Frohna PA; Joyce JN; Schneider JS
    Mov Disord; 1997 Mar; 12(2):148-58. PubMed ID: 9087972
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [A mouse model of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine induced parkinsonism: effect of norepinephrine terminal destruction].
    Nishi K; Kondo T; Narabayashi H
    No To Shinkei; 1987 Jul; 39(7):663-72. PubMed ID: 3314916
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.